Ranked #3,048 of 8,699 institutional investors
Decheng Capital LLC
Menlo Park, CA
$670M
US stock portfolio at live prices · today +$13.0M (+1.98%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $685M
- Change from Q2 2026
- −$46.7M (−6.38%)
- Positions
- 10 · 0 new, 2 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$2.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesCGON 77.9%NUVB 14.8%ACRS 2.11%LYEL 1.40%RCUS 1.00%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | 6,371,669 | $522M | 77.9% | Unchanged |
| NUVB Nuvation Bio Inc. | 25,954,439 | $98.9M | 14.8% | Unchanged |
| ACRS Aclaris Therapeutics, Inc. | 4,041,736 | $14.1M | 2.11% | Unchanged |
| LYEL Lyell Immunopharma, Inc. | 692,050 | $9.4M | 1.40% | Unchanged |
| RCUS Arcus Biosciences, Inc. | 425,079 | $6.7M | 1.00% | Reduced −9% |
| UPB Upstream Bio, Inc. | 2,724,868 | $5.4M | 0.81% | Unchanged |
| EQ Equillium, Inc. | 4,447,308 | $5.0M | 0.74% | Unchanged |
| AARD Aardvark Therapeutics, Inc. | 3,917,299 | $3.9M | 0.58% | Unchanged |
| ZNTL Zentalis Pharmaceuticals, Inc. | 1,323,327 | $1.8M | 0.27% | Unchanged |
| PYXS Pyxis Oncology, Inc. | 326,810 | $549K | <0.1% | Unchanged |